• OPEN AN ACCOUNT
Indian Indices
Sensex
82,268.25 1,161.60
( 1.43%)
Global Indices
Nasdaq
52,245.46 -165.29
(-0.32%)
Dow Jones
7,531.52 -39.42
(-0.52%)
Hang Seng
60,560.79 1,785.29
(3.04%)
Nikkei 225
10,782.38 -0.49
(0.00%)
Forex
USD-INR
94.03 -0.38
(-0.40%)
EUR-INR
104.75 -1.32
(-1.24%)
GBP-INR
125.52 -1.66
(-1.31%)
JPY-INR
0.59 0.00
(-0.72%)

EQUITY - MARKET SCREENER

Ambalal Sarabhai Enterprises Ltd
Industry :  Trading
BSE Code
ISIN Demat
Book Value()
500009
INE432A01017
7.7615866
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
AMBALALSA
60.39
273.04
EPS(TTM)
Face Value()
Div & Yield %
0.59
10
0
 

Novartis enters into exclusive promotion and distribution agreement with Novartis Healthcare
Sep 08,2026

Novartis India has entered into an Exclusive Promotion and Distribution Agreement dated 8 September 2026 with Novartis Healthcare (NHPL).

Under the terms of the said Agreement, the Company has been granted the rights to exclusively promote and distribute NHPL's retina portfolio comprising the products Accentrix® (ranibizumab) and Pagenax® (brolucizumab) for the territory of India.

The Agreement is expected to support the Company's entry into the ophthalmology therapy area and expand its commercial portfolio.

The upfront consideration payable by the Company to NHPL shall be Rs 10 crore.